Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Spitfire Pharma LLC has 4 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 3 distinct examiners and 2 distinct art units, combining examiner variation with some art-unit overlap.
BANERJEE, KOYELI is the busiest examiner, with 2 pending matters. Reviewing those matters together may reveal useful consistency in prosecution strategy, while the remaining actions should be handled according to their individual examiner and art-unit contexts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BANERJEE, KOYELI | 2 | 33.3% | +0.0% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +56.1% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18467608 | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | BANERJEE, KOYELI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18943449 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | ESPINOSA, CLAUDIA EDILMA | — |
| 17180827 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18943449 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | ESPINOSA, CLAUDIA EDILMA | 1654 | DP | Final Rejection | — | Pending | Nov 11, 2024 |
| 18503065 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | BANERJEE, KOYELI | 1658 | §103DP | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18467608 | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | BANERJEE, KOYELI | 1658 | §102§103Other | Non-Final OA | — | Pending | Sep 14, 2023 |
| 17180827 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | AUDET, MAURY A | 1654 | §112 | Final Rejection | — | Pending | Feb 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpitfire Pharma LLC has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Koyeli Banerjee has the most, with 2 of Spitfire Pharma LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
